-
Daiichi Sankyo2019-12-12 16:00:02The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
-
Daiichi Sankyo2019-12-12 16:00:02Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with
-
Daiichi Sankyo2019-12-12 16:00:02Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World
-
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2
-
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with
-
Daiichi Sankyo2020-08-03 09:31:20ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in
-
Daiichi Sankyo2019-12-12 16:00:02Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with
-
Daiichi Sankyo2019-08-22 10:15:01Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to
-
Daiichi Sankyo2020-08-03 09:31:50FDA Approves Daiichi Sankyo’s TURALIO® (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare
-
Daiichi Sankyo2019-08-07 13:30:01Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the